Oruka Therapeutics (ORKA) announced that it is expected to be added to the Nasdaq Biotechnology Index (NBI). Oruka’s addition will become effective prior to market open on Monday, December 23rd, 2024. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by companies classified as either biotechnology or pharmaceutical companies according to the Industry Classification Benchmark.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ORKA:
- Oruka Therapeutics: Strong Q3 and Strategic Advances
- Oruka Therapeutics files to sell 8.72M shares of common stock for holders
- Oruka Therapeutics reports Q3 EPS ($1.46), consensus (40c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
